NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis $31.26 +1.52 (+5.11%) Closing price 04:00 PM EasternExtended Trading$31.26 -0.01 (-0.02%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About QuidelOrtho Stock (NASDAQ:QDEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get QuidelOrtho alerts:Sign Up Key Stats Today's Range$30.21▼$31.8850-Day Range$24.46▼$37.4252-Week Range$23.77▼$49.45Volume1.57 million shsAverage Volume1.08 million shsMarket Capitalization$2.11 billionP/E RatioN/ADividend YieldN/APrice Target$44.33Consensus RatingHold Company OverviewQuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More… QuidelOrtho Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreQDEL MarketRank™: QuidelOrtho scored higher than 90% of companies evaluated by MarketBeat, and ranked 103rd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageQuidelOrtho has only been the subject of 3 research reports in the past 90 days.Read more about QuidelOrtho's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.57% Earnings GrowthEarnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about QuidelOrtho's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.34% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.61 Percentage of Shares Shorted6.34% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.40 News SentimentQuidelOrtho has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for QuidelOrtho this week, compared to 7 articles on an average week.Search Interest11 people have searched for QDEL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesQuidelOrtho’s SWOT analysis: diagnostics firm’s stock faces pivotal yearMay 26 at 9:11 AM | investing.comQuidelOrtho to Participate in Upcoming Investor ConferencesMay 22, 2025 | businesswire.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 27, 2025 | Altimetry (Ad)QuidelOrtho Corp (QDEL) Stock Price Down 3.32% on May 19May 19, 2025 | gurufocus.comQuidelOrtho (QDEL) Faces Tariff Impact, Maintains 2025 OutlookMay 13, 2025 | gurufocus.comQuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)May 12, 2025 | seekingalpha.comWhy Is QuidelOrtho (QDEL) Stock Soaring TodayMay 9, 2025 | msn.comJefferies Upgrades QuidelOrtho (QDEL)May 9, 2025 | msn.comSee More Headlines QDEL Stock Analysis - Frequently Asked Questions How have QDEL shares performed this year? QuidelOrtho's stock was trading at $44.55 at the start of the year. Since then, QDEL shares have decreased by 29.8% and is now trading at $31.26. View the best growth stocks for 2025 here. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) posted its quarterly earnings data on Wednesday, May, 7th. The company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.13. The company's quarterly revenue was down 2.6% on a year-over-year basis. Read the conference call transcript. Who are QuidelOrtho's major shareholders? Top institutional shareholders of QuidelOrtho include T. Rowe Price Investment Management Inc. (16.97%), Vanguard Group Inc. (10.01%), Invesco Ltd. (5.65%) and AQR Capital Management LLC (3.94%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2025Today5/27/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,000Year Founded1979Price Target and Rating Average Stock Price Target$44.33 High Stock Price Target$61.00 Low Stock Price Target$25.00 Potential Upside/Downside+41.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.97) Trailing P/E RatioN/A Forward P/E Ratio13.59 P/E GrowthN/ANet Income$-2,027,000,000.00 Net Margins-72.84% Pretax Margin-76.59% Return on Equity3.78% Return on Assets1.80% Debt Debt-to-Equity Ratio0.71 Current Ratio1.22 Quick Ratio0.69 Sales & Book Value Annual Sales$2.76 billion Price / Sales0.76 Cash Flow$24.23 per share Price / Cash Flow1.29 Book Value$44.75 per share Price / Book0.70Miscellaneous Outstanding Shares67,626,000Free Float66,584,000Market Cap$2.11 billion OptionableOptionable Beta0.13 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:QDEL) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.